These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24162638)

  • 21. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R; Levy C
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New meningococcal vaccines in the UK.
    Lloyd KE; Paul SP; Garg AK
    Community Pract; 2015 Nov; 88(11):28-30, 33. PubMed ID: 26749613
    [No Abstract]   [Full Text] [Related]  

  • 23. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
    Larrauri A; Cano R; García M; Mateo Sd
    Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anti-meningococcal vaccines: diversity of vaccination policies and recommendations].
    Gendrel D
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S70-6. PubMed ID: 22883370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meningococcal B immunisation in New Zealand: why haven't we seen the data?
    Bolland M
    N Z Med J; 2008 Mar; 121(1270):107-9. PubMed ID: 18364764
    [No Abstract]   [Full Text] [Related]  

  • 28. Perils of launching a new vaccination campaign.
    Dobson F
    BMJ; 2014 Apr; 348():g2449. PubMed ID: 24699385
    [No Abstract]   [Full Text] [Related]  

  • 29. Indirect effects by meningococcal vaccines: herd protection versus herd immunity.
    Bröker M
    Hum Vaccin; 2011 Aug; 7(8):881-2. PubMed ID: 21785283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neisseria meningitidis serogroup A vaccines: an overview.
    Vergnano S; Heath P
    Expert Rev Vaccines; 2003 Aug; 2(4):571-82. PubMed ID: 14711341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conjugate vaccine-induced immunological priming is not protective against acute meningococcal C infection.
    Spoulou VI; Moschou CK; Tzanakaki G; Theodoridou MC
    Vaccine; 2007 Oct; 25(41):7012-3. PubMed ID: 17707961
    [No Abstract]   [Full Text] [Related]  

  • 33. Community cluster of meningococcal disease by Neisseria meningitidis serogroup C in Andalusia, Spain, March to May 2011.
    Mayoral Cortés JM; Torres Butrón E; García Fernández M; Herrador Ortiz Z; Huarte Osakar S; Santos Luque R; Pérez Morilla E; Guillén Enriquez J
    Euro Surveill; 2012 Sep; 17(36):20261. PubMed ID: 22971329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An effective serogroup B meningococcal vaccine.
    Domínguez F; Menéndez J; Ochoa R
    Vaccine; 2006 Nov; 24(49-50):7025-6. PubMed ID: 16879900
    [No Abstract]   [Full Text] [Related]  

  • 35. [Microbiology and public health: new challenges in surveillance and control of meningococcal disease].
    Abad R; Vázquez JA
    Enferm Infecc Microbiol Clin; 2012 Feb; 30(2):53-5. PubMed ID: 22305483
    [No Abstract]   [Full Text] [Related]  

  • 36. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.
    Trotter CL; Ramsay ME
    FEMS Microbiol Rev; 2007 Jan; 31(1):101-7. PubMed ID: 17168998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can we defeat meningococcal disease in low and middle income countries?
    Greenwood B; Chiarot E; MacLennan CA; O'Ryan M
    Vaccine; 2012 May; 30 Suppl 2():B63-6. PubMed ID: 22607901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of meningococcal serogroup C conjugate vaccine in Scotland.
    Mooney JD; Christie P; Robertson C; Clarke SC
    Clin Infect Dis; 2004 Aug; 39(3):349-56. PubMed ID: 15307001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The first effect of the national vaccination campaign against meningococcal-C disease: a rapid and sharp decrease in the number of patients].
    de Greeff SC; de Melker HE; Spanjaard L; van den Hof S; Dankert J
    Ned Tijdschr Geneeskd; 2003 Jun; 147(23):1132-5. PubMed ID: 12822525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Choices about meningococcal vaccination.
    Way AB
    N Engl J Med; 2004 Mar; 350(11):1156; author reply 1156. PubMed ID: 15014195
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.